Inside Novo Nordisk’s GLP-1 Patent Strategy for Semaglutide

In GLP-1 therapeutics, timing matters as much as innovation.

Novo Nordisk’s semaglutide patent families reflect a long-term approach to portfolio construction—one that compounds value as filings mature into grants.
PatSeer enables this kind of lifecycle analysis at scale, turning patent data into decision-ready intelligence for IP leaders.

Where patent data meets decision-grade intelligence. https://bit.ly/3sZr3iy

#PatSeer #Patents #Patentlandscape #PatentPortfolio #patentsearchai #aipatentsearch #AI #Intellectualproperty #Patentanalysis #PatentInsights #IPIntelligence #PatentDatabase #PatentAnalytics #PatentIntelligence #PharmaInnovation #Biotech #GLP1 #IPStrategy #DrugDiscovery